Avidity Partners Management LP Ascendis Pharma A/S Transaction History
Avidity Partners Management LP
- $885 Million
- Q4 2024
A detailed history of Avidity Partners Management LP transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Avidity Partners Management LP holds 62,000 shares of ASND stock, worth $10.3 Million. This represents 0.96% of its overall portfolio holdings.
Number of Shares
62,000
Previous 119,000
47.9%
Holding current value
$10.3 Million
Previous $17.8 Million
51.97%
% of portfolio
0.96%
Previous 1.09%
Shares
7 transactions
Others Institutions Holding ASND
# of Institutions
236Shares Held
60.2MCall Options Held
80.3KPut Options Held
216K-
Ra Capital Management, L.P. Boston, MA10.1MShares$1.68 Billion22.55% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.53MShares$918 Million3.52% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.1MShares$847 Million10.24% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.45MShares$739 Million0.98% of portfolio
-
Janus Henderson Group PLC London, X04.38MShares$727 Million0.32% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $9.26B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...